Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection
Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection
This study evaluates a new method of testing the lymph nodes in the armpit of patients with
 breast cancer for tumor involvement. All participants involved in this study will undergo an
 injection of a small amount of iron dissolved in liquid followed by an ultrasound of the
 axilla that will make previously invisible lymph nodes visible, allowing them to be sampled
 in an outpatient setting.
Lymph nodes are small collections of tissue all over the body that drain bodily fluid. These
 axillary lymph nodes are important in evaluating breast cancer since, if they are positive,
 it suggests that the cancer cells have spread outside of the breast. The current standard of
 care is for most breast cancer patients undergoing surgery to have a sentinel lymph node
 biopsy which is a procedure to take a sample of the lymph nodes in the armpit (also called
 the axilla) during their breast surgery. However this intraoperative biopsy comes with
 certain risks such as arm swelling or lymphedema, arm pain, arm numbness/tingling, and/or
 psychological distress from waiting for the results or the possibility of further
 interventions. In order to avoid this and have a result before surgery, this study will
 explore a nonsurgical method of sampling these lymph nodes. Normally suspicious lymph nodes
 are hard to find accurately by exam and ultrasound.

 A new method has been developed that involves injecting a small amount of iron dissolved in
 liquid into the breast that gets absorbed by the lymph nodes making them bright on ultrasound
 and possible to biopsy. This method has been shown to have results as accurate as standard
 sentinel lymph node biopsy by comparing them in the operating room. This study will now
 investigate performing these ultrasounds and biopsies in the office as well as compare these
 results to the results of the standard sentinel lymph node biopsy in the operating room. The
 results of this study could help future breast cancer patients to avoid invasive sampling and
 all of the accompanying risk as well as give patients and the care team an idea of the extent
 of disease sooner in order to guide management.
Inclusion Criteria:

 -  Female patients at least 21 years old

 -  Patients with invasive ductal carcinoma staged T1 or T2 with estrogen receptor and
 progesterone receptor positive (ER+/PR+) who are scheduled for sentinel lymph node
 biopsy

 -  Patients with Ductal Carcinoma In Situ (DCIS) (high or low grade) who are scheduled
 for sentinel lymph node biopsy including:

 -  Patients having a mastectomy

 -  Patients with palpable DCIS

 -  Patients undergoing breast conservation with large (>5cm) area of DCIS

 -  Patients with signed consent to participate

 Exclusion Criteria:

 -  Preoperative palpable axillary lymphadenopathy

 -  Preoperative ultrasound demonstrating suspicious adenopathy

 -  Previous axillary dissection or previous lymph node biopsy

 -  Patients with Invasive Lobular Carcinoma

 -  Patients who are pregnant